A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1

NCT03679455 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Obinutuzumab 25 MG/ML

Sponsor

Polish Myeloma Consortium

Collaborators

[object Object]
[object Object]